Skip to main content

IL-4 AND IL-13 SIGNALING PLAYS A ROLE IN THE INFLAMMATORY PROCESS OF CHRONIC SPONTANEOUS URTICARIA (CSU), RESULTING IN ITCH AND HIVES1-4

Watch the video to see how DUPIXENT works.

View Transcript

DUPIXENT BINDS TO IL-4Rα, INHIBITING IL-4 AND IL-13 SIGNALING

Dual inhibition of IL-4 and IL-13 signaling helps5:

REDUCE TYPE 2
INFLAMMATION

REDUCE ITCH

REDUCE HIVES

The mechanism of dupilumab action
has not been definitively established.

TYPE 2 INFLAMMATION MAY CONTRIBUTE TO DISEASE CHRONICITY IN CSU

Watch the video to see how DUPIXENT works.

View Transcript

Type 2 cytokines, including IL‑4 and IL‑13, may
contribute to
multiple aspects
of mast cell activation and degranulation2‑4,6‑11

Diagram of Dupixent® (dupilumab) inhibiting IL-4 and IL-13 signaling

Enhance IgE and IgG production

Increase expression of FcεRIa

Enhance neurosensitization to pruritogens
(eg, histamine, other mediators)b

Increase recruitment of type 2 inflammatory cells
(eg, basophils, eosinophils, B cells, and T cells)c

FcεRI, high-affinity IgE receptor.

a This leads to mast cell priming and degranulation. Activated mast cells release IL-4 and IL-13 and contribute to type 2 inflammation in CSU.8

b Itch signals can, in turn, induce further immune activation and release of inflammatory mediators, creating a feedback loop.12,13

c IL-5 may also play a role in skin homing of eosinophils as well as in their maturation and survival.14

d Th2 cells produce IL-4 and IL-13, which enhance B cell production of IgE and IgG antibodies.6,8

e Mast cells can be activated through pathways that are IgE dependent or independent, leading to degranulation and the release of histamine
and other immune mediators.11

Watch the video to see how DUPIXENT works.

View Transcript

DUPIXENT IS THE ONLY DUAL
INHIBITOR OF IL-4 AND IL-13
SIGNALING5,6

DUPIXENT binds to IL-4
receptor alpha, inhibiting IL-4
and IL-13
induced
inflammatory responses

The mechanism of dupilumab action has not been definitively established.

  • fDimerization is when 2 protein subunits combine to form a larger complex. IL-4 signaling through type I receptor requires dimerization of the Il-4Rα with the gamma chain. IL-4 or Il-13 signaling through type II receptor requires dimerization of IL-4Rα with Il-13Rα1.

IL-4 SIGNALING
(TYPE I RECEPTOR)

IL-4/IL-13 SIGNALING (TYPE II RECEPTOR)

TAKE A LOOK AT
PATIENT PROFILES

Consider whether your appropriate CSU patient may be a
candidate for DUPIXENT.

Identify Patients